SeaWith, a Seoul-based food tech startup, has entered into a strategic supply agreement with UK biotech firm 3D Bio-Tissues (3DBT). The deal focuses on the integration of 3DBT’s proprietary cell culture media to reduce SeaWith’s production costs for cultivated beef by 30%. The partnership targets the primary barrier to entry in the South Korean market: high price points. According to APAC-SCA data, 65% of South Koreans cite price as the leading factor in cultivated protein adoption.
Core Metrics
- Cost Efficiency: Targeted 30% reduction in production costs for SeaWith’s cultivated beef.
- Deal Value: Agreement valued at £300,000 (~$400,000 USD) for 3D Bio-Tissues.
- SeaWith Funding: $8 million raised to date.
- BSF Enterprise Funding: Parent company of 3DBT raised $19.8 million this month to expand operations.
- Consumer Sentiment: Only ~20% of South Korean consumers are willing to pay a premium for cultivated meat; 25% would purchase it if it achieved price parity with conventional beef.
Strategic Analysis of the SeaWith and 3D Bio-Tissues Partnership
The collaboration centers on City-Mix®, 3DBT’s "macromolecular crowder." The supplement functions as a "cell booster" by mimicking naturally crowded biological environments, which enhances the bioactivity of growth factors and enzymes. This process increases cell proliferation and yield while eliminating the need for expensive animal inputs like fetal bovine serum (FBS).
For SeaWith, the deal accelerates the commercialization of its Welldone™ brand, which utilizes seaweed-based technology for 3D scaffolds. The company is currently leveraging South Korea’s Regulation-Free Special Zone in Gyeongbuk, a government initiative designed to bypass regulatory "red tape" and fast-track the scaling of alternative proteins.
Corporate Structure & Pipeline
- SeaWith: Leading South Korean startup specializing in seaweed-based cultivation technology. Initial product launch focus: Beef meatballs.
- 3D Bio-Tissues (3DBT): A subsidiary of BSF Enterprise PLC. Specializes in scaffold-free structured tissues and media supplements across multiple animal species.
- Regulatory Roadmap: SeaWith is eyeing national approval in South Korea and has expressed interest in joining the Food Tech Research Support Center in Uiseong-gun (slated for 2027).
Technical Specification
- City-Mix®: A premium macromolecular crowder that creates volume-exclusion effects in aqueous solutions. It stabilizes biomolecules and improves the thermodynamic activity of proteins within the culture medium.
- Synergy: Optimized for use with SeaWith’s Hanwoo-derived muscle stem cells, supporting both robustness and scalability in the production of high-quality tissue.
Regulatory Landscape: the South Korea case
South Korea is emerging as a primary R&D hub for the APAC region. SeaWith joins domestic competitors CellMeat and Simple Planet in seeking regulatory green lights. The South Korean government continues to fund dedicated facilities to transition the country into a central player in the global protein supply chain alongside Japan, China, and Singapore.
→ For more industry insights, explore all Tocco Reports & Toccographics
